<DOC>
	<DOCNO>NCT00688415</DOCNO>
	<brief_summary>This multi-center , Phase I study new investigational drug , VTX-2337 , may stimulate immune system help fight cancer . The purpose study assess safety investigational drug identify high dose well-tolerated . The pharmacology VTX-2337 also evaluate .</brief_summary>
	<brief_title>Safety Pharmacologic Study VTX-2337 Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Other specific eligibility criterion may apply . Examination investigator necessary fully determine eligibility . Ability willingness provide write informed consent Histologically cytologically confirm solid tumor lymphoma Locally advanced metastatic disease Life expectancy least 16 week ECOG performance status 0 1 Acceptable physical exam laboratory test study entry Willingness use medically acceptable contraception A negative serum pregnancy test woman reproductive potential Anticancer therapy within 2 week Treatment investigational agent within 4 week Systemic corticosteroid within 2 week requirement systemic immunosuppressive therapy Known brain metastasis unless stable least 28 day Active autoimmune disease Insulindependent diabetes mellitus Clinically significant cardiac disease within 6 month Significant infection fever within 1 week Pregnant breastfeeding females Other condition circumstance could interfere study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>